Cambridge Isotope Laboratories, Inc. Announces Expansion of 13C Capacity at Ohio Plant

TEWKSBURY,Massachusetts,Aug. 12,2020 --Cambridge Isotope Laboratories,Inc.(CIL),theworld leader in stable isotope chemistry and the separation ofcarbon-13 (13C),recently completed a significant expansion of its13Cseparation facility.In 1987,CIL took the initiative to construct the world'slargest 13C isotope-separation plant,Cambridge Isotope Separations,LLC (CIS),locatedon 33 acresin Xenia,Ohio.13C is a critical starting material supporting development of new research and diagnostic chemicals.Following expansions in 1996,2012,and 2015,CIL embarked on a new expansionin 2018 which was completed earlier this year.This most recent expansion increased production capacity of13C by 25%.

"CILhas been investing and growing with customers continuously forthe past 33 years," states Cliff Caldwell,CEO."Ourisotopemarkets have been expanding,and the volumes requiredby our committed customershave made it necessary that wecontinue to expand tomeet the market needs.Cambridge IsotopeLabshas many years of experience designing and building carbon isotope-separationsystems and we are the leading technology expert in that space.Thisin-houseknowhow makes us the supplier of choicebecause of the certainty wecan reliably scaleour production processes quickly and effectively."

"The expansion was initiated in response to the strong and growing demand by our customers for13C and13C urea," saysMikeSteiger,VP of Project Engineering and Execution. "There is an increasing need for isotopes for medical investigations and13C plays an important role."The13C isotope is known to be used in a variety of applications for environmental analysis,medical research,and medical diagnostics.Medicaldiagnosis-based CO2breathtests,such as13C urea(used to detectHelicobacter pyloribacterialinfection)and13Cmethacetinfor liver disease,canaidin theprevention of invasive procedures.

13C is a nonradioactive (stable) element which makes up approximately 1% of all carbon atoms in nature. At the CISplant in Ohio,natural carbon monoxide (containing ~1% 13C) is cryogenically liquefied and then distilled through several long specially designed distillation columns,which make it one of the world's longest distillation systems of any kind.CIL has continuously demonstrated its expertise in the area of cryogenic distillation and maintain our place as the world's leading producerof13C isotope.The end-product of this process is carbon monoxide that is greater than 99% 13C,whichis then used to manufacture any one of the thousands of isotope-labeled products offered by CIL.

About Cambridge Isotope Laboratories,Inc. 

CIL is the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research,environmental,neonatal,pharmaceutical,medical diagnostic,OLED, and industrial markets. CIL is an operating business owned by Otsuka Pharmaceuticals. The CIL business consists of two facilities in the Boston,MA, area; a large isotope-enrichment production plant in Xenia,OH; CIL China; CIL Canada; ABX in Dresden,Germany; and Eurisotop in Saclay,France. 

For more information on CIL,visit isotope.com.

Related Images

image1.jpg